Posted by Michael Wonder on 11 Mar 2018
The relative importance of clinical, economic, patient values and feasibility criteria in cancer drug reimbursement in Canada: a revealed preferences analysis of recommendations of the pan-Canadian Oncology Drug Review 2011–2017
20 January 2018 - Most Canadian provinces and territories rely on the pan-Canadian Oncology Drug Review to provide recommendations regarding public reimbursement of cancer drugs.
The pCODR review process considers four dimensions of value—clinical benefit, economic evaluation, patient-based values and adoption feasibility—but they do not define weights for individual decision criteria or an acceptable threshold for any of the criteria.
Given this implicit review process, it is of interest to understand which factors appear to carry the most weight in pCODR recommendations using a revealed preferences approach.
